Peer-Reviewed Journal Details
Mandatory Fields
Vincenz, L,Jager, R,O'Dwyer, M,Samali, A
2013
June
Molecular Cancer Therapeutics
Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
Published
()
Optional Fields
REGULATES AGGRESOME FORMATION PROTEASOME INHIBITOR PS-341 ER STRESS INDUCED APOPTOSIS MESSENGER-RNA TUMOR-GROWTH ANTIMYELOMA ACTIVITY TRANSCRIPTION FACTOR THERAPEUTIC OPTION DRUG-RESISTANCE
12
6
831
843
Multiple myeloma is characterized by the malignant proliferating antibody-producing plasma cells in the bone marrow. Despite recent advances in therapy that improve the survival of patients, multiple myeloma remains incurable and therapy resistance is the major factor causing lethality. Clearly, more effective treatments are necessary. In recent years it has become apparent that, as highly secretory antibody-producing cells, multiple myeloma cells require an increased capacity to cope with unfolded proteins and are particularly sensitive to compounds targeting proteostasis such as proteasome inhibitors, which represent one of the most prominent new therapeutic strategies. Because of the increased requirement for dealing with secretory proteins within the endoplasmic reticulum, multiple myeloma cells are heavily reliant for survival on a set of signaling pathways, known as the unfolded protein response (UPR). Thus, directly targeting the UPR emerges as a new promising therapeutic strategy. Here, we provide an overview of the current understanding of the UPR signaling in cancer, and outline its important role in myeloma pathogenesis and treatment. We discuss new therapeutic approaches based on targeting the protein quality control machinery and particularly the IRE1 alpha/XBP1 axis of the UPR.
DOI 10.1158/1535-7163.MCT-12-0782
Grant Details
Publication Themes